R K Chavda

Ranbaxy, Гургаон, Haryana, India

Are you R K Chavda?

Claim your profile

Publications (2)0 Total impact

  • Source
    R K Chavda · L Laxmi · B S Nair · K Gandewar ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Before the 1990s, treatment of psychoses centred on conventional agents whose tolerability was limited by extrapyramidal symptoms (EPS). The past decade has seen the emergence of newer generation of antipsychotic agents. These agents provide better negative symptom efficacy, less impaired cognition and lower risk of extrapyramidal syndromes. Aripiprazole, a new atypical antipsychotic drug, displayed efficacy similar to risperidone and haloperidol in numerous clinical trials. Aripiprazole does not cause significant prolactin elevation and is associated with a low rate of clinically significant weight gain compared with other atypical antipsychotics. Aripiprazole is a study drug for treating schizophrenia and has a novel pharmacologic profile. Aripiprazole provides a new treatment option with limited adverse effects for patients in need of antipsychotic therapy. The present study is a 4-week, open-labelled, randomized postmarketing clinical study conducted using aripiprazole as the study drug. Fixed doses of 15mg of the drug were administered throughout the study. A total of 249 patients with a primary diagnosis of schizophrenia or schizoaffective disorder were randomized. Efficacy measures included the Positive And Negative Syndrome Scale (PANSS) total, PANSS positive, PANSS negative and general psychopathology. Patients were evaluated for efficacy parameters at the end of 2(nd) week and also at the end of study. Unlike the other antipsychotics, aripiprazole was not associated with significant EPS, increase in body weight or increase in QTc interval. Aripiprazole, effective against positive and negative symptoms, is a safe and well-tolerated potential treatment for schizophrenia and schizoaffective disorder.
    Indian Journal of Psychiatry 04/2004; 46(2):150-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study discusses incidence and clinical profile of pulmonary involvement in leptospirosis in South Gujarat. It also tries to evaluate the effect of high dose glucocorticoid pulse therapy (GPT) on it. A study was carried out on hundred and two patients of suspected leptospirosis, referred to Government Medical College, New Civil Hospital, Surat between June 99 to September 99. The incidence, clinical profile, and specific investigations were studied in patients having pulmonary involvement. Some of the patients were given high dose glucocorticoid pulse therapy. Their outcomes were compared with those who had not been given glucocorticoid pulse therapy. Out of seventy seven seropositive patients 13 (16.8%) developed pulmonary involvement. Mortality was two out of eight patients in the group that received GPT and four out of five patients in the group that did not receive GPT. Two patients who died in the steroid treated group received the drug after 12 hours of onset of dyspnea. High dose GPT should be given as early as possible after the onset of dyspnea to all the patients with pulmonary involvement in leptospirosis. Further studies are required to establish the GPT as a standard regimen in treatment of pulmonary involvement in leptospirosis.
    The Journal of the Association of Physicians of India 10/2001; 49:901-3.